That variation is normal and doesnt mean the medication has stopped working
[DOI] [PubMed] [Google Scholar] 147.Hemamy M., Pahlavani N., Amanollahi A., Islam S.M.S., McVicar J., Askari G., Malekahmadi M
People taking injectable semaglutide can lose on average 15 percent of their weight while a clinical trial found that more than one-third of participants on tirzepatide lost 25 percent of their weight over 72 weeks
Most of the rapid increase in peak plasma radioactivity was related to the parent drug, implying a low level of first pass metabolism
GLP1 RAs, thus, are not recommended to be prescribed for patients with a history of pancreatitis and should be discontinued if pancreatitis symptoms develop
If you prescribe outside your training without proper education, you risk discipline for negligence or practicing below the standard of care